Article
09 Oct 2025
生命科学行业License-in/out合同争议要点分析（三）：不竞争条款
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in China
AUTHORS CONTENT
Article
03 Oct 2025
汉坤 • 观点 | CAR-T/NK监管路在何方 — 体细胞临床研究工作指引（征求意见稿）要点解读
Article
01 Oct 2025
观点 | 生命科学行业License-in/out合同争议要点分析（四）：首付款是否可能退回？
Article
01 Oct 2025
药企出海新热点：管线分拆"SON"模式的实践解读
Article
25 Sep 2025
Han Kun • Quick Comment | Is The Transmission Of Cross-border Genomic Data Between China And The United States Blocked? Biden Data Executive Order Quick Review
Article
24 Sep 2025
More Than 60 Innovative Drugs Were Approved: Interpretation Of The Highlights Of The 2022-2023 China Drug Review Report
Article
24 Sep 2025
2022-2023 China Medical Device License-In/Out Project Core Clause Data Analysis
Article
23 Sep 2025
61款创新医疗器械获批：2023年度中国医疗器械注册工作报告亮点解读
Article
22 Sep 2025
Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China
Article
19 Sep 2025
汉坤 • 观点 | 细胞与基因治疗领域又一利好：研究者发起的临床研究（IIT）管理办法正式落地
Article
19 Sep 2025
汉坤 • 观点 | 解读2024年版《赫尔辛基宣言》最新亮点 — 全球医学研究伦理准则系统性更新
Article
18 Sep 2025
观点 | 《医疗器械管理法（草案）》十大亮点快评
Article
16 Sep 2025
2024年NewCo与药械License-in/out项目核心条款数据分析与对比
Article
12 Sep 2025
解读人类遗传资源管理最新问答：人源细胞系、肿瘤异种移植模型（CDX/PDX）、CAR-T治疗材料监管问题